Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745783 | 0.82 | TGFBR1 (0.40) | TGFBR1CYP1A2CYP2C9ALDH1A1ADORA2A | |
| SCHEMBL4255030 | 0.79 | DYRK1A (0.38) | TGFBR1CYP1A2CYP2C9ALDH1A1KCNJ1 | |
| SCHEMBL4249759 | 0.79 | DYRK1A (0.38) | TGFBR1CYP1A2CYP2C9ALDH1A1KCNJ1 | |
| SCHEMBL4253831 | 0.79 | KCNJ1 (0.35) | TGFBR1CYP1A2CYP2C9ALDH1A1KCNJ1 | |
| SCHEMBL10238918 | 0.75 | CYP1A2 (0.56) | TGFBR1CYP1A2CYP2C9ALDH1A1KDM4E | |
| SCHEMBL18041741 | 0.75 | TGFBR1 (0.55) | TGFBR1 | |
| SCHEMBL22595101 | 0.74 | ALDH1A1 (0.38) | CYP2A6ALDH1A1KDM4EMAPT | |
| SCHEMBL4250153 | 0.74 | TGFBR1 (0.63) | TGFBR1CYP1A2ALDH1A1KDM4E | |
| SCHEMBL13745282 | 0.74 | PIK3CG (0.57) | — | |
| SCHEMBL17754951 | 0.73 | TGFBR1 (0.41) | TGFBR1CYP1A2CYP2C9ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PI4KA, PIP4K2A | TGFBR1 444/4885CYP1A2 2574/4885CYP2C9 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.